Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells
-
Published:2018-02-12
Issue:3
Volume:24
Page:282-291
-
ISSN:1078-8956
-
Container-title:Nature Medicine
-
language:en
-
Short-container-title:Nat Med
Author:
Mathew Nimitha R, Baumgartner Francis, Braun Lukas, O'Sullivan David, Thomas Simone, Waterhouse Miguel, Müller Tony A, Hanke Kathrin, Taromi Sanaz, Apostolova Petya, Illert Anna L, Melchinger Wolfgang, Duquesne Sandra, Schmitt-Graeff Annette, Osswald Lena, Yan Kai-Li, Weber Arnim, Tugues Sonia, Spath Sabine, Pfeifer Dietmar, Follo Marie, Claus Rainer, Lübbert Michael, Rummelt Christoph, Bertz Hartmut, Wäsch Ralph, Haag Johanna, Schmidts Andrea, Schultheiss Michael, Bettinger Dominik, Thimme Robert, Ullrich Evelyn, Tanriver Yakup, Vuong Giang Lam, Arnold Renate, Hemmati Philipp, Wolf Dominik, Ditschkowski Markus, Jilg Cordula, Wilhelm Konrad, Leiber Christian, Gerull Sabine, Halter Jörg, Lengerke ClaudiaORCID, Pabst Thomas, Schroeder Thomas, Kobbe Guido, Rösler Wolf, Doostkam Soroush, Meckel Stephan, Stabla Kathleen, Metzelder Stephan K, Halbach SebastianORCID, Brummer Tilman, Hu Zehan, Dengjel Joern, Hackanson Björn, Schmid Christoph, Holtick Udo, Scheid Christof, Spyridonidis AlexandrosORCID, Stölzel Friedrich, Ordemann Rainer, Müller Lutz P, Sicre-de-Fontbrune Flore, Ihorst Gabriele, Kuball Jürgen, Ehlert Jan E, Feger Daniel, Wagner Eva-Maria, Cahn Jean-Yves, Schnell Jacqueline, Kuchenbauer Florian, Bunjes Donald, Chakraverty Ronjon, Richardson Simon, Gill Saar, Kröger Nicolaus, Ayuk Francis, Vago Luca, Ciceri Fabio, Müller Antonia M, Kondo Takeshi, Teshima TakanoriORCID, Klaeger Susan, Kuster BernhardORCID, Kim Dennis (Dong Hwan), Weisdorf Daniel, van der Velden Walter, Dörfel Daniela, Bethge Wolfgang, Hilgendorf Inken, Hochhaus Andreas, Andrieux Geoffroy, Börries Melanie, Busch HaukeORCID, Magenau John, Reddy Pavan, Labopin Myriam, Antin Joseph H, Henden Andrea S, Hill Geoffrey R, Kennedy Glen A, Bar Merav, Sarma Anita, McLornan Donal, Mufti Ghulam, Oran Betul, Rezvani Katayoun, Shah Omid, Negrin Robert S, Nagler Arnon, Prinz Marco, Burchert Andreas, Neubauer Andreas, Beelen Dietrich, Mackensen AndreasORCID, von Bubnoff Nikolas, Herr Wolfgang, Becher BurkhardORCID, Socié Gerard, Caligiuri Michael A, Ruggiero Eliana, Bonini Chiara, Häcker Georg, Duyster Justus, Finke Jürgen, Pearce Erika, Blazar Bruce R, Zeiser Robert
Publisher
Springer Science and Business Media LLC
Subject
General Biochemistry, Genetics and Molecular Biology,General Medicine
Reference53 articles.
1. Pfirrmann, M. et al. Prediction of post-remission survival in acute myeloid leukaemia: a post-hoc analysis of the AML96 trial. Lancet Oncol. 13, 207–214 (2012). 2. Sengsayadeth, S.M. et al. Allo-SCT for high-risk AML-CR1 in the molecular era: impact of FLT3/ITD outweighs the conventional markers. Bone Marrow Transplant. 47, 1535–1537 (2012). 3. Serve, H. et al. Sorafenib in combination with intensive chemotherapy in elderly patients with acute myeloid leukemia: results from a randomized, placebo-controlled trial. J. Clin. Oncol. 31, 3110–3118 (2013). 4. Röllig, C. et al. Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial. Lancet Oncol. 16, 1691–1699 (2015). 5. Metzelder, S.K. et al. High activity of sorafenib in FLT3-ITD-positive acute myeloid leukemia synergizes with allo-immune effects to induce sustained responses. Leukemia 26, 2353–2359 (2012).
Cited by
204 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
|
|